Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Kymera Therapeutics (NASDAQ:KYMR) received mixed analyst ratings with an updated average 12-month price target of $39.5, reflecting a 3.95% increase from the previous target. Analysts from JP Morgan, Stifel, B of A Securities, and Wells Fargo adjusted their ratings and price targets, indicating varied expectations for the company's performance. Despite the optimistic price targets, Kymera faces challenges such as a significant revenue decline of -50.5% over 3 months and below-average returns on equity and assets, alongside a high debt-to-equity ratio.
February 23, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Kymera Therapeutics received mixed analyst ratings, with an updated average 12-month price target of $39.5. The company faces significant challenges, including a substantial revenue decline and poor financial performance metrics.
The mixed analyst ratings and the updated price target reflect a cautiously optimistic outlook for Kymera Therapeutics. However, the company's significant revenue decline and below-average financial performance metrics, such as ROE and ROA, alongside a high debt-to-equity ratio, suggest potential challenges ahead. These factors contribute to a neutral short-term impact score, as the positive analyst sentiment may be offset by the company's financial difficulties.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100